Stay updated on SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial page.

Latest updates to the SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedThe page revision label was updated from v3.5.2 to v3.5.3, indicating a newer version of the study record. This reflects a minor administrative update that does not change the study content or eligibility criteria.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision note updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check45 days agoChange DetectedUpdated the follow-up time frame for several outcomes. The period from 91 days through completion of follow-up (estimated 24 months) was replaced with 91 days through 12 months post-SBRT or 90 days after the last defactinib dose, whichever comes first (estimated 12 months 5 days).SummaryDifference0.3%

- Check52 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check81 days agoChange DetectedAdministrative updates to the study record show revised start and completion dates and a new last-update timestamp. The updated timeline reflects changes to the trial's schedule.SummaryDifference0.4%

Stay in the know with updates to SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT and FAK Inhibitor in Advanced Pancreas Adenocarcinoma Clinical Trial page.